Vaxcyte, Inc. PCVX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -30.6%-10.9pp | -25.6%-5.2pp | -20.8%+0.2pp | -21.7%+7.4pp | -19.7%+10.2pp | |
| Return on assets | -28.1%-9.5pp | -23.5%-4.7pp | -19.5%+0.6pp | -20.3%+7.4pp | -18.6%+9.6pp | |
| Return on invested capital | -37.6%-8.3pp | -32.9%-3.4pp | -31.9%+5.1pp | -32.7%+15.3pp | -29.3%+22.4pp | |
| Liquidity | ||||||
| Current ratio | 7.5×-10.2× | 7.9×-4.8× | 8.8×-9.1× | 11.1×-6.8× | 17.7×+0.3× | |
| Quick ratio | 7.5×-10.2× | 7.9×-4.8× | 8.8×-9.1× | 11.1×-6.8× | 17.7×+0.3× | |
| Cash ratio | 1.1×-2.5× | 0.9×-1.9× | 1.4×-7.1× | 2×-4.3× | 3.6×-3.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $21.48-8.9% | $19.73-27.2% | $21.24-23.1% | $22.58+33.3% | $23.58+32.8% | |
| Valuation | ||||||
| Market capitalization | $8.36B+72.0% | $6.04B-40.8% | $4.68B-65.1% | $4.4B-47.9% | $4.86B-25.4% | |
| Enterprise value | $8.22B+78.6% | $5.98B-39.5% | $4.48B-63.8% | $4.18B-47.4% | $4.6B-22.4% | |
| Price / book | 2.8×+1.3× | 2.2×-0.8× | 1.6×-2.3× | 1.4×-2.8× | 1.5×-1.8× | |
| Free cash flow yield | -9.3%+0.6pp | -11.1%-6.4pp | -11.9%-8.2pp | -10.8%-5.0pp | -9.9%-3.4pp | |
| Earnings yield | -11.3%-0.8pp | -12.7%-8.1pp | -14.1%-10.3pp | -12.4%-6.6pp | -10.5%-3.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vaxcyte, Inc.'s ratios come from?
- Every ratio is computed from Vaxcyte, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.